Italfarmaco Spa

Gianni Gromo

Flavio Leoni

Patrizia Caretto

Paolo Mascagni

Giorgio Bertolini

Alberto Sala

Teresa Sciumbata

Fabrizio Marcucci

Francesca Benedini

Massimo Pinori

Silvio Levi

Gianluca Fossati

Gianfranco Pavich

Silvana Cappelletti

Daniela Modena

Giuseppe Legname

Giancarlo Dona

Roberto Barani

Giuliana Porro

Paola Giuliani

Pierluigi Lucietto

Diego Brocchetti

Heparin derivatives are disclosed that may be used to inhibit formation of metastases. One series of heparin derivatives of the invention are N-acylated with monocarboxylic acids or dicarboxylic acids and have molecular weights from about 1000 Daltons to about 30,000 Daltons. Another series of heparin derivatives of the invention have average molecular weights ranging from about 1000 to 3000 daltons, and are optionally N-acylated with residues from aliphatic monocarboxylic or dicarboxylic acids.

Heparin derivatives having antimetastatic activity

Oligopeptides derived from C-reactive protein fragments

Peptides endowed with antiinflammatory activity

Diesters of carbonic acid disubstituted with primary, secondary or tertiary amine groups, pharmaceutically acceptable salts thereof, and their use as antiviral and inti-inflammatory agents.

Diesters of carbonic acid endowed with antiviral and anti-inflammatory

Nucleotide sequences coding for ribosome inactivating proteins

Compounds of formula I ##STR1## wherein R represents hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.5 -C.sub.7 cycloalkyl, methylene-dioxy or phenyl, which may be substituted by one or two groups independently selected from hydroxy, halogen, nitro, C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 alkoxy; R.sub.1 and R.sub.2 independently represent hydrogen, COOR.sub.3, --CONR.sub.4 R.sub.5, ##STR2## --OCONR.sub.4 R.sub.5, --OCOR.sub.3, --NR.sub.4 R.sub.5, --OCOOR.sub.6, --NR.sub.3 COR.sub.7, --NR.sub.CONR.sub.4 R.sub.5, --N.dbd.CH--NR.sub.4 R.sub.5, NO.sub.2, CN, OH, SR.sub.3, wherein R.sub.3 is hydrogen or C.sub.1 -C.sub.6 alkyl, R.sub.4 and R.sub.5 independently are hydrogen or C.sub.1 -C.sub.6 alkyl, R.sub.6 is C.sub.1 -C.sub.6 alkyl, and R.sub.7 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 alkoxy, with the proviso that R.sub.1 and R.sub.2 cannot be hydrogen at the same time; X is oxygen or sulphur; Y represents a C.sub.2 -C.sub.6 alkylene chain or a C.sub.5 -C.sub.7 cycloalkylene group; and their pharmaceutically acceptable salts are provided and their use in pharmaceutical compositions which may be used in the treatment of cardiovascular diseases.

Benzoxazinone and benzothiazinone derivatives having cardiovascular

Growing community of inventors

Sesto S. Giovanni, Italy

Gianni Gromo